Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 Expected year-over-year growth of approximately 15% to 18% compared with Q3 2025 ───────────────────────────────────────────────────────────────────────────────── Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million PARSIPPANY, NJ, October 14, 2026 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million. The expected revenue range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter of 2026 and an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025. The estimated revenue presented in this release is preliminary and unaudited, is based on information currently available to management, and remains subject to completion of the Company’s quarter-end closing procedu…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
INTERPACE BIOSCIENCES INC
IDXGOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 14, 2026, Interpace Biosciences, Inc. (the “Company”) issued a press release announcing preliminary results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Press release in this filing
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue →Company context
We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.